Hong Kong Beverage Stock News

China Resources Power Holdings (SEHK:836) has released operating figures for March and the past 3 months of 2026, highlighting higher total net generation and a larger contribution from photovoltaic assets despite weaker wind conditions. See our latest analysis for China Resources Power Holdings. The recent operating update comes as the share price trades at HK$19.86, with a 7 day share price return of 5.47% and a year to date share price return of 12.65%, alongside a 5 year total shareholder...

Akeso (SEHK:9926) is back in focus after presenting positive Phase II COMPASSION-26 data at the 2026 AACR meeting, highlighting cadonilimab plus chemotherapy in advanced pancreatic ductal adenocarcinoma. See our latest analysis for Akeso. Akeso's share price is trading at HK$131.6 after a 16.15% year-to-date share price return, with recent clinical updates arriving alongside a 12.96% 90-day share price gain and a very large 3-year total shareholder return of 207.12%. This suggests momentum...

HKBN (SEHK:1310) has just posted its H1 2026 scorecard, with trailing 12 month revenue of HK$11.4b and basic EPS of HK$0.14, setting the tone for how the year is shaping up after a period of faster earnings growth. The company has seen revenue move from HK$4,841.8m in H2 2024 to HK$5,734.3m in H1 2025 and HK$5,394.3m in H2 2025, while basic EPS shifted from HK$0.0067 to HK$0.0821 and HK$0.0685 across those same halves. This gives investors a clear line of sight on how the top and bottom line...

New Gonow Recreational Vehicles (SEHK:805) has released its FY 2025 numbers with first half revenue of C¥411.7 million and basic EPS of C¥0.0326, set against trailing twelve month revenue of C¥871.4 million and EPS of C¥0.03 that sit within a period of weaker earnings and a 3.5% net margin. Over recent reporting halves the company has seen revenue move between C¥421.97 million and C¥442.19 million, with basic EPS ranging from C¥0.0549 to C¥0.0028. Trailing earnings have been described as high...

Regulatory backdrop for China Construction Bank The People's Bank of China is tightening oversight of harmful competitive practices and financial risks, which puts regulatory attention front and center for investors watching China Construction Bank (SEHK:939) and other large Chinese lenders. See our latest analysis for China Construction Bank. At a share price of HK$8.95, China Construction Bank has seen firm momentum recently, with a 10.77% 1 month share price return and a 39.15% 1 year...

From what we can see, insiders were net buyers in HG Semiconductor Limited's ( HKG:6908 ) during the past 12 months...

The market was pleased with the recent earnings report from Smoore International Holdings Limited ( HKG:6969 ), despite...

Li Ning Company Limited ( HKG:2331 ) shareholders are probably feeling a little disappointed, since its shares fell...

The market for CK Hutchison Holdings Limited's ( HKG:1 ) shares didn't move much after it posted weak earnings...

If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point. The stock has returned 0.7% over the last 7 days, 25.8% over the last 30 days, 8.3% year to date, and 25.2% over 1 year, while the 3 year and 5 year returns sit at 32.8% and 23.1% declines respectively. These mixed returns mean context really matters. Recent company updates, financing decisions,...

Context for COSCO SHIPPING Holdings after recent performance COSCO SHIPPING Holdings (SEHK:1919) has drawn attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside modest annual revenue growth and weaker net income growth. See our latest analysis for COSCO SHIPPING Holdings. At a share price of HK$14.75, COSCO SHIPPING Holdings has seen short term momentum cool after a 10.9% 3 month share price return. However, the 1...

CSPC Pharmaceutical Group (SEHK:1093) has flagged a key product milestone after its subsidiary reported that a Phase Ib/III trial of Sirolimus for Injection in advanced malignant PEComa met its primary efficacy endpoint in China. See our latest analysis for CSPC Pharmaceutical Group. The HB1901 trial news sits alongside a mixed share price picture, with CSPC Pharmaceutical Group’s HK$8.98 latest close coming after a 5.8% year to date share price return but an 8.5% 3 month share price decline,...

Setting the scene for Kuaishou Technology Kuaishou Technology (SEHK:1024) has drawn investor attention after a period of weak share price performance, with the stock showing negative returns over the past month, past 3 months, and year to date. See our latest analysis for Kuaishou Technology. At a latest share price of HK$43.7, Kuaishou’s weak recent momentum, including a 30 day share price return of 17.62% decline and a 1 year total shareholder return of 13.33% decline, points to fading...

Industrial and Commercial Bank of China (SEHK:1398) has drawn fresh attention after shareholders approved a final ordinary cash dividend of RMB 1.689 per 10 shares, with clear timelines for both A share and H share payouts. See our latest analysis for Industrial and Commercial Bank of China. The dividend decision comes on the back of a strong run in the shares, with a 30 day share price return of 10.50% and a year to date share price return of 14.51%. The 1 year total shareholder return of...

KLN Logistics Group (SEHK:636) is in focus after announcing several leadership changes, including a new Chief Financial Officer and executive board appointments, aimed at supporting financial discipline, global expansion, and workforce transformation. See our latest analysis for KLN Logistics Group. At a share price of HK$6.74, KLN Logistics Group has seen mixed momentum, with a 7 day share price return of 2.90% contrasting with a 90 day share price return decline of 4.80% and a 5 year total...

As global markets react positively to geopolitical de-escalations, the Asian market is experiencing a cautiously optimistic sentiment. This environment presents an intriguing backdrop for exploring penny stocks, which, despite their somewhat outdated label, continue to offer potential value through smaller or newer companies. By focusing on those with robust financials and clear growth trajectories, investors may find promising opportunities in these under-the-radar stocks that could offer...

As you might know, China Mobile Limited ( HKG:941 ) just kicked off its latest first-quarter results with some very...

As global markets react positively to signs of de-escalation in the Middle East, Asian markets are also experiencing renewed investor interest. Penny stocks, a term that may seem outdated but still relevant, often refer to smaller or newer companies that can offer substantial growth potential at lower price points. By identifying those with strong financials and clear growth paths, investors can uncover hidden gems within this niche market segment.

Shareholders might have noticed that Pop Mart International Group Limited ( HKG:9992 ) filed its full-year result this...

Leapmotor (SEHK:9863) has introduced the D19, described as the world's first premium SUV using a centralized QNX based software platform. The system integrates the digital cockpit, advanced driver assistance, and connectivity functions into a single safety certified domain. This launch marks the first mass produced vehicle to consolidate these core software defined features on advanced QNX platforms. For investors watching the electric vehicle space, this move puts software architecture at...

Sinopharm Group (SEHK:1099) opened 2026 with Q1 revenue of about CNY 17.8b and basic EPS of CNY 0.52, setting the tone against a trailing twelve month profile that shows revenue of roughly CNY 574.7b and EPS of CNY 2.28. Over recent quarters investors have seen quarterly revenue move from about CNY 141.7b in Q1 2025 to CNY 145.4b in Q3 2025 and CNY 143.7b in Q4 2025, with basic EPS ranging from CNY 0.47 to CNY 3.29 across that period as the business cycled through different earnings levels...

If you are looking at Cathay Pacific Airways and asking whether the current share price fairly reflects its prospects, the valuation story is where things get interesting. The stock last closed at HK$11.96, with returns of 1.2% over 7 days, a 0.5% decline over 30 days, a 5.3% decline year to date, 43.4% over 1 year, 90.9% over 3 years and 108.7% over 5 years. This performance may lead you to question whether the current price still offers value or has already priced in much of the recent...

Genscript Biotech (SEHK:1548) has proposed amendments to its memorandum and articles of association. The planned changes relate to the company’s core corporate governance framework and could influence shareholder rights and internal decision making. For investors watching Genscript Biotech at a share price of HK$14.19, the move to adjust its foundational documents comes alongside mixed longer term share performance. The stock is up 6.6% over the past week, 33.9% over the past month, 10.9%...

Those following along with EVA Precision Industrial Holdings Limited ( HKG:838 ) will no doubt be intrigued by the...